Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ciloa","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ciloa Secures \u20ac5 Million for the Development of Its New Generation of Biomedicines and Vaccines Using Exosomes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Ciloa

    Menu

    Ciloa

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ciloa

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ciloa Secures €5 Million for the Development of Its New Generation of Biomedicines and Vaccines Using Exosomes

              Details:

              These funds will be used notably for the development of a new generation of natural vaccines using exosomes to prevent SARS-CoV-2 infection, including the variants responsible for the severe form of Covid-19.

              Lead Product(s): Exosomes-based Vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Bpifrance

              Deal Size: $5.5 million Upfront Cash: Undisclosed

              Deal Type: Funding March 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY